Vivos Therapeutics, Inc.
VVOS- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001716166
No open-market purchases or sales by Vivos Therapeutics, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $242.7K in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Vivos Therapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 23 | 20 | −3 |
| Shares | 245.1K | 466.8K | +221.8K (+90.5%) |
| Value | $630.7K | $2.00M | +$1.37M (+217.6%) |
New holders (2)
Institutions that held Vivos Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Anson Funds Management LP | 242,583 | $1.04M | 0.13% |
| Cutter & CO Brokerage, Inc. | 38,100 | $163.4K | 0.04% |
Sold out (5)
Institutions that held Vivos Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Omers Administration Corp | 25,000 | $65.3K |
| Sabby Management, LLC | 20,502 | $53.5K |
| Two Sigma Investments, LP | 20,482 | $53.5K |
| Millennium Management LLC | 12,001 | $31.3K |
| Voisard Asset Management Group, Inc. | 1 | $3 |